Microba Life Sciences Limited (ASX:MAP)

Market Cap	37.12M -27.4%
Revenue (ttm)	14.76M -5.8%
Net Income	-20.72M
EPS	-0.03
Shares Out	700.31M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	24,000
Open	0.0530
Previous Close	0.0530
Day's Range	0.0530 - 0.0530
52-Week Range	0.0360 - 0.1050
Beta	2.10
Analysts	n/a
Price Target	n/a
Earnings Date	Oct 27, 2026

About Microba Life Sciences

Microba Life Sciences Limited provides microbiome testing, supplements, and analysis services in Australia, Europe, New Zealand, the United Arab Emirates, the United Kingdom, the United States, Asia, and Ireland. It operates in two segments, Testing Services and Supplements, and Research and Development. The company also develops pathology, therapeutics, and diagnostics services based on the human gut microbiome. In addition, it offers MetaPanel, a metagenomic test for pathogen detection; MetaXplore that provides a range of diagnostics solution...

• Industry: Diagnostics & Research
• Sector: Healthcare
• Founded: 2017
• Country: Australia
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: MAP

Financial Performance

In fiscal year 2026, Microba Life Sciences's revenue was 14.76 million, a decrease of -5.81% compared to the previous year's 15.67 million. Losses were -20.72 million, 38.7% more than in 2025.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Sep 17, 2026

Data Sources Report a data error